Rheumatoid arthritis is a multistep disorder associated with autoimmune features of yet unknown etiology. Implication of viruses such as Epstein-Barr virus (EBV) in rheumatoid arthritis pathogenesis has been suspected on the basis of several indirect observations, but thus far, a direct link between EBV and rheumatoid arthritis has not been provided. Here we show that a large fraction of T cells infiltrating affected joints from a patient with chronic rheumatoid arthritis recognizes two EBV transactivators (BZLF1 and BMLF1) in a major histocompatibility complex-restricted fashion. Responses to these EBV antigens by synovial lymphocytes from several other chronic rheumatoid arthritis panents were readily detectable. Thus these results suggest a direct contribution of EBV to chronic rheumatoid arthritis pathogenesis. They also demonstrate for the first time the occurrence of T cell responses against EBV transactivating factors, which might be central in the control of virus reactivation.
Summary
Rheumatoid arthritis is a multistep disorder associated with autoimmune features of yet unknown etiology. Implication of viruses such as Epstein-Barr virus (EBV) in rheumatoid arthritis pathogenesis has been suspected on the basis of several indirect observations, but thus far, a direct link between EBV and rheumatoid arthritis has not been provided. Here we show that a large fraction of T cells infiltrating affected joints from a patient with chronic rheumatoid arthritis recognizes two EBV transactivators (BZLF1 and BMLF1) in a major histocompatibility complex-restricted fashion. Responses to these EBV antigens by synovial lymphocytes from several other chronic rheumatoid arthritis panents were readily detectable. Thus these results suggest a direct contribution of EBV to chronic rheumatoid arthritis pathogenesis. They also demonstrate for the first time the occurrence of T cell responses against EBV transactivating factors, which might be central in the control of virus reactivation.
R
heumatoid arthritis (RA) 1 is an incapacitating disease characterized by chronic joint inflammation and progressive destruction of articular structures, which affects about 1% of the population worldwide (1) . Its etiology remains unresolved, but there is ample evidence that T cells contribute directly to RA pathogenesis. This is supported in particular by (a) the widespread T cell infiltration of affected synovial membranes from RA patients (2) , (b) the genetic predisposition of RA, which is associated with certain MHC class II haplotypes (3) (4) (5) (6) (7) , and (c) the beneficial effects ofT cell-depleting treatments in RA patients (8, 9) . Despite this, the specificity of T cells infiltrating RA lesions and their pathogenicity at late stages of the disease remain obscure. With respect to the first issue, several candidate antigens recognized by synovial T cells have been proposed. For instance, a pathogenic role of T cell-mediated immune responses against connective tissue proteins such as type II collagen Is supported by the occurrence of increased proliferative responses to these Ag of synovial T cells as compared to PBL in R.A patients (10, 11) . Besides endogenous compounds, several arthritogenic Ag ofmycobacterial IAbbreviations used in this paper: BLC, B lymphoblastoid cells; RA, rheumarred arthritis; SFL, synovlal fluid lymphocytes; SML, synovial membrane-derived lymphocytes.
origin, such as stress proteins, have been shown to elicit synovial T cell responses in some RA patients, although the importance of stress proteins in synovial T cell-mediated responses against mycobactena still remains controversial (12) (13) (14) (15) . Furthermore, a variety of viruses have been proposed as RA causative agents (1) . In particular, EBV has long been linked to RA on theoretical grounds (e.g., because of the existence of shared epitopes between EBV proteins and RA autoantigens) and from clinical studies suggesting in particular increased anti-EBV serological responses in a fraction of RA patients (16, 17) . However the physiopathological relevance of these observations is still unclear, particularly because no evidence for anti-EBV responses within RA lesions have been provided thus far. The pathogenicity of T cells at late stages of RA is also a controversial issue. On the one hand, both the extensive diversity of the TCRs expressed by synovial lymphocytes isolated from most chronic RA patients (18) and the evidence for joint destruction and/or active synovitis in the absence of local lymphoid infiltrate in animal models and in humans (19) argues against a major role of T cells in the perpetuation of RA. On the other hand, a specific Agdriven T cell recruitement to the joints at late stages of RA is indirectly supported by studies demonstrating oligoclonal T cell expansions within the affected joints of several chronic RA patients (18) . Patient 19  B1  ND  ND  ND  ND  A'2401  B2  ND  ND  ND  ND  B'3501  B3  ND  ND  ND  ND  B'3501  B4  ND  ND  ND  ND  B'3501   All T cell clones listed in this table expressed distinct TCRs as In an attempt to evaluate the repertoire diversity and specificity of T cells activated during chronic RA, we recently studied the specificity ofsynovial T lymphocytes derived from patients with typical long lasting chronic RA. Because in several patients the majority of synovial T cells were CD8 +, both CD4 + ceils, which presumably comprise T cells reactive against RA susceptibility HLA class II alleles, and CD8 + cells were analyzed. CD4 + and/or CD8 + synovial T cell responses towards autologous and/or allogeneic B lymphoblastoid cells (BLC) expressing one or several autologous HLA alleles were detected m four of six patients studied (David-Ameline, J., M.A. Peyrat, and M. Bonneville, unpublished results). Furthermore, in two patients, an enrichment for autologous BLC-reactive cells among synovial T cells was evidenced by comparative analyses of patients' PBL and synovial T cells (20; results summarized in Table 1 ). Together, these results suggested frequent expansions of cells reactive against autologous BLC during chronic RA. Here we make use of this material to characterize by an expression cloning approach the antigens recognized by synovial T cells derived from these patients. A dominant response of synovial T cells to two EBV transactivators is demonstrated, thus suggesting an Ag-driven recruitment ofT cells to the synovium in these patients and a possible role of these EBV-specific T cells in chronic RA pathogenesis. More generally, this study provides the first clear-cut evidence for T cell responses against EBV proteins playing a key function during virus replication. Such responses might have a central role in the control of virus spreading under physiological and pathological situations. Polyarthritis remained active dunng the whole follow-up penod. This patient received low-dose predmsone (7-12 mg/d) throughout. Synovlal fluid lymphocytes (SFL) were obtained during synovial fluid analysis before steroid infiltrations. Synov]al membrane lymphocytes (SML) were obtained dunng surgery, performed 27 mo after collection of SFL. All other patients fulfilled at least four out of seven critena for RA (21) . Antx-EBV serology was studied in patients 1, 5, and 6. All had serum antibodies against at least one of the following EBV proteins: RA nuclear antigen, EpsteinBarr nuclear antigen 1, early antigens, and viral capsld antigens. These patients showed dramatically elevated titers of serum antibodies against early antigens (range 160 to >640).
Materials and Methods

Patients
Cells
PBL and SFL were maintained in RPMI 1640 supplemented with 10% human serum, 1 mM L-glutamine (hereafter referred to as culture medmm), and recombinant IL-2 (100 IU/ml). T cell clones were isolated and resumulated once a month as follows. Synovlal T cells (either total or sorted by means of TCR BV reNon-specific mAb) were seeded at 0.3 cells/well and cultured in culture medium supplemented with IL-2 (100 IU/ml), purified PHA (leucoagglutinin, 0.5 Ixg/ml) and irradiated (30 Gy) allogeneic feeder cells. Such culture conditions allow the growth of virtually all T cells and do not introduce any bias in the T cell repertoire, as demonstrated by flow cytometry analysis using TCR BV region-specific mAb and by analysis of TCR CDR3 length distribution (22; Llm, A., M.A. Peyrat, and M. Bonneville, unpublished data). Coreceptor phenotype, TCR features, and HLA restnction of T cell clones are detailed elsewhere (20) and summarized in Table 1 .
Expression Cloning of T Cell Antigens
Construction of the cDNA Library. Poly(A) + KNA was prepared from patient 1 BLC using an mRNA purification kit (Pharmacla Fine Chemicals, Plscataway, NJ). cDNAs were synthesized using a Zap-cDNA synthesis kit (Stratagene Inc., La Jolla, CA). BstXI adaptators (Invltrogen, San Diego, CA) were hgated to the cDNAs. After size fractionauon, cDNAs were cloned into pcDNA3 (Invitrogen) digested with BstXI. Recombinant plasmids were electroporated into Escherichia coli X1-1 and selected with ampicilhn (50 Ixg/ml). The library was divided into 288 pools of 200 cDNA clones. Each pool was amplified to saturation, and plasmid DNA was extracted by the alkaline lysis method.
Transfection of COS Cells. Transfection was performed by the DEAE-dextran-chloroquine method as described (23, 24) . In brief, 1.5 × 104 COS cells were transfected with 100 ng ofplasmid containing the relevant HLA DNA and 100 ng of a pool of the cDNA library. The genomic HLA-A*0101, which was kindly provided by Dr. J. Girdlestone (Medical Research Council, Cambridge, UK), was cloned into pcDNA3. Genomic HLA-A*0201 DNA, HLA-A*2401 cDNA, and HLA-A*0301 were kindly provided by T. Boon (Ludwig Institute, Brussels, Belgium). HLA-A*0201 was cloned into pSV2 vector, HLA-A*2401 and A*0301 were in pcDNA3. The cDNA HLA-B*3501, which was kindly provided by Dr. L. Satz (Laboratory of Immunogenetics, Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina), was cloned into pcDNA3. HLA-B*4002 and Cw*0102 were cloned from the B cell cDNA library. Transfectants were then tested for their ability to stimulate TNF production by T cells (see below). Each positive pool was subcloned into 800-1,600 bacteria, which were each tested for their ability to trigger T cell clone TNF release after expression m COS cells cotransfected with relevant HLA DNA. Positive clones were sequenced by the dideoxy chain termlnauon method.
T Cell Stimulation Assay. T cells were added to COS cells
24--48 h after transfection, and culture supernatants were harvested 6-18 h later and tested for TNF content by measuring culture supematant cytotoxicity to WEHI164 clone 13 in a colorimetric assay (25) .
Production of Truncated BMLF1 or BZLF1 cDNA. Truncated BMLF1 cDNA fragments, generated by partial digests, were cloned into pcDNA3, pcDNA3 vector was also used to clone a 140-bp fragment after PCR amphfication of the ASaclI BMLF1 fragment with ohgonucleotides BM1 (5'-GCGGATCCGCCACCATG-3'), introducing a BamHI site for cloning and an internal ATG, and SP6 (5'-ATTTAGGTGACACTATAG-3'). Truncated BZLF1 cDNA fragments, generated by partial digests, were cloned into pcDNA3.
Peptide Assays
Lyophilized peptides (Chiron Mimotopes Corp., Victoria, Australia) were dissolved at 20 mg/ml in DMSO, diluted at 2 mg/ml in 10 mM aceuc acid, and stored at -80°C. In cytotox]city assays, 2.5 × 104 51Cr-labeled A2.10 T cells were incubated m the presence of peptides at various concentrations, and SlCr release was measured after 3 h at 37°C. Percentage of specific lysls was calculated as described in (22) . In TNF release assays, 2.5 × 10 4 T cells were incubated for 5 h with the peptldes at vanous concentrations, and the amount of TNF released in the supernatant was estimated by the WEHI 164 cytotoxiclty assay.
T Cell Cytotoxicity and Proliferation Assays
Both kinds of assays were performed as previously described (22) . In brief, cytotoxic activity ofT cell clones toward BLC was measured by a standard 4-h SlCr-release assay at two E/T ratios. T cell clone cytolytic potential was estimated by lectin-dependent kilhng of target cells (i.e., by evaluating T cell cytotoxic activity in the culture medium supplemented with 0.5 Ixg/ml of purified PHA [leucoagglutmln]). Proliferative activity of responder T cells was esumated after a 48-h culture of 10 4 responder cells with 2.5 × 104 irradiated BLC m 100 txl of culture medium supplemented with rlL-2, followed by an overnight pulse with 0.5 IxCI of tritiated thymidine.
COS Transfection Assays Using Polyclonal T Cell Lines
Patients' PBL, SFL, or SML were cultured for 15 d in culture medium supplemented with rlL-2 and leucoagglutmin. Under such culture condiuons, no TCR repertoire skewings were introduced, as suggested by comparative analysis of TCR BV CDR3 length distribution of some synovial samples before and after culture (Llm, A., M.A. Peyrat, and M. Bonneville, unpublished observations). After washing, cells were maintmned for 7 d in culture medium with rI1-2 but without lectin, to decrease spontaneous TNF release. TNF secretion in culture supematant was then estimated as described above, after incubating for 6 h varying numbers of responder T cells (from 103 to 105) together with confluent COS cells transfected 24 h earlier with HLA and/or EBV cDNAs.
Results
We recently showed that a large fraction ofsynovial T cell clones derived from two patients (hereafter referred to as patients 1 and 19) proliferated in vitro when exposed to au-A B T~ ~ Figure 1 . 9-mers, 4 10-mers, and I 11-mer) encoded by the 140 bp fragment defined m B and containing consensus binding "anchor" res]dues to HLA-A*0201 were synthesized Significant T cell clone lysls was observed with peptlde GLCTLVAML but with none of the 9 other peptIdes tested. Data obtained with pepude TLVAMLEETI are shown as a negative example. (D) Induction of A2.10 clone TNF release by synthetic BMLF1 peptldes. Peptide GLCTLVAML but none of the 9 other peptides tested snmulated production of TNF by clone A2.10. Peptlde TLVAMLEETI is shown as a negative control.
tologous BLC (20) . The fact that autologous BLC-reactive clones were found in both CD4 + and CD8 + T cell subsets suggested that this reactivity was a general feature of synovial T cells, regardless of their coreceptor phenotype (20) . In an attempt to establish the fine specificity of these cells, cDNAs from a patient 1 BLC hbrary were screened for their ability to trigger TNF production by synovial T cell clones after transient cotransfection into COS cells together with DNAs encoding the appropriate MHC allele (23, 24) . Because this approach is well suited for cloning MHC class I-but not class II-restricted Ags (23) , this analysis focused on the characterization of Ag recognized by CD8 + synovial T cell clones. (Table 1) , was analyzed first. Using the COS transfection approach (23, 24), we identified 2 out of 270 cDNA pools that induced TNF production by clone A2.10 after cotransfection with HLA-A*0201 DNA. Out of 800 clones derived from one positive pool, one 1,591-bp cDNA induced TNF production by A2.10 cells when cotransfected with HLA-A*0201 DNA (Fig. 1 A) . Its sequence was identical to that of an EBV gene, BMLF1, encoding a 439-amino acid protein expressed during the early stage of the virus rephcative cycle (26, 27) . Because of the transactivating properties of the BMLF1 product (26) , this protein could upregulate the expression of endogenous Ag recognized in turn by the synovial T cell clone rather than being recognized itselE To address this question, truncated BMLF1 cDNAs were tested for their ability to activate A2.10 TNF release after cotransfection with HLA-A*0201 DNA. A BMLF1 region encoded by a HinclI/SacH 140-bp sequence was shown to be stimulatory (Fig. 1 B) . Of several peptides located in this region and synthesized on the basis of their consensus bmding capacities to HLA-A*0201 (28), only the nonapeptide GLCTLVAML (amino acids 259-267) induced autocytotoxicity and TNF release by A2.10 cells (Fig. 1, C and D) . This formally demonstrates a classic MHC-restricted recognition of the BMLF1 protein.
Recognition of the EBV
Recognition of the EBV Transactivator BZLFI by the Synovial T Cell Clone A 17.11. The antigenic specificity of another synovial T cell clone from patient 1, A17.11, which recognized autologous BLC in an HLA-Cw*0102-restricted fashion (Table 1) , was then studied. Because this clone did not react with COS cells cotransfected with BMLF1 and HLA-Cw*0102 cDNAs, the cloning strategy described above was applied once again (23) . One cDNA, which conferred recognition of COS cells by A17.11 cells after cotransfection with HLA-Cw*0102 DNA (Fig. 2) , contained a 753-bp cDNA insert encoding BZLF1, another early EBV protein with transactivating properties (29) .
Dominant Response of Synovial T Cells from Patient 1 to EB V Transactivators.
We then tested the reactivity toward BMLF1-or BZLFl-transfected COS cells of the whole panel of BLC 1-reactive CD8 + synovial T cell clones with a known HLA restriction element (A*0201, B'4002, or Cw*0102) and expressing distinct T cell receptors (Table 1) . BZLF1 recogniuon by the HLA-Cw*0102-restncted T cell clone A17.11. TNF released by T cell clone A17.11 was measured after incubataon with COS cells transfected with BZLF1 and HLA-Cw*0102 cDNA or with each of these cDNA. The experimental protocol is the same as described m the legend to Fig. 1 .
Whereas one other clone reacted with BZLF1 in the context of HLA-Cw*0102 (clone A17.10, Table 2 ), most T cell clones recognized BZLF1 in the context of HLA-B*4002 (representative data shown in Fig. 3 A and summarized in Table 2 ). The characterization of T cell clones recognizing BZLF1 in the context of HLA-B*4002, for which peptide anchor motifs are well defined (28) , allowed us to determine whether, similarly to BMLF1, this transactivator was recognized as a peptidic antigen presented by MHC products. In support of this, BZLF1 cDNA fragments able to trigger TNF production by T cell clone A14.7 after cotransfection with HLA-B*4002 DNA into COS cells could be defined (Fig. 3 B) , and a synthetic peptide located in the stimulatory BZLF1 region was shown to trigger T cell clone autocytotoxicity and TNF release (Fig. 3, C and D) .
That there is an enrichment for T cells reacting against BZLF1/BMLF1 antigens within the inflamed joints of patient 1 is supported by two lines of evidence. First, T cells expressing TCR-[3 chains with V[3/J[3 combinations and lengths identical to those expressed by EBV-reactive T cell clones accounted for "°30% of synovial T cells, but only a minute fraction of peripheral blood T cells from patient 1 (Table 1) . Second, TNF production by short-term cultured synovial fluid and peripheral blood T cells from patient 1 induced by COS cells transfected with either HLA-A*0201, B'4002, or Cw*0102 DNAs together with either BZLF1 or BMLF1 cDNAs differ dramatically: compare the amounts of TNF released by synovial as compared to peripheral blood T cells after exposure to COS cells transfected with BMLF1 and A*0201 DNAs (Fig. 4, upper left) or BZLF1 and B'4002 DNAs (Fig. 4, lower middle) . Signif- icantly, dominant responses to BZLF1/B*4002 and BMLF1/ A*0201 were seen with synovial membrane-derived lymphocytes recovered 27 mo after the first sample (Fig. 4) , indicating that these reactivities are common and long-lasting features of synovial lymphocytes derived from patient 1.
T Cell Responses to BMLF1/BZLF1 in Other Chronic RA
Patients. An enrichment for autologous BLC-reacfive T cells within the synovium in another chronic RA patient (patient 19) was suggested by the fact that unlike PBL clones, 4 of 12 randomly chosen CD8 ÷ synovial clones derived (Table 3) . T cell responses to BMLF1 and BZLF1 were also studied at the polyclonal level in patient 19 and in several HLA-A*02 + chronic RA patients. In agreement with the above results, a clear TNF response was detected when incubating short-term cultured synovial T cells from patient 19 with HLA-B*3501/BZLF1-transfected COS cells (Fig. 5, right) . TNF production by T cell clones was estimated after incubation with COS cells transfected with HLA-B*3501 cDNA and either BMLF1 or BZLFt cDNAs. -, TNF secretion <1.0 pg/ml (Table 4 ; and reference 20), none of them were able to kill to detectable levels BLC which otherwise triggered their proliferation (Table 4 and data not shown). This could not be explained by a lack of lyric potential because (a) these clones efficiently lysed BLC in the presence of lectin (Table 4) , and (b) addition of appropriate synthetic peptides to synovlal T cell clones resulted in efficient peptide self presentation and autocytotoxicity ( Figs. 1 and 3) . Actually, this peculiar behavior is most probably explained by the T cell clone's fine specificity. Indeed, although BLC are known to express predominantly EBV latent proteins, rare cells supporting a fully productive EBV infection have been detected in most BLC lines studied (30) . Such cells could efficiently trigger proliferation of T cell clones directed against lytic proteins, although their lysis by the corresponding CTL might not be detectable in standard cytotoxicity assays.
Discussion
We study here the fine specificity of synovial T cells derived from several chronic P,-A patients. Our results indicate that in two patients, a large fraction of T cell clones derived from synovial fluid and synovial membranes of inflamed joints reacts against two EBV transactivators, BMLF1 and BZLF1. Moreover, responses against these EBV proteins were evidenced within short-term-cultured synovial T cells derived from several other RA patients. These observations raise questions regarding (a) the mechanisms governing T cell recruitment to the synovium during chronic RA, (b) the implication of EBV in chronic RA pathogenesis and the possible pathogenic role of EBV-reactive T cells, (c) the possible dominance of anti-EBV T cell responses in RA patients toward a specific set of proteins, and (d) the general significance and consequences of EBV transactivator recognition by T cells.
Regarding the first issue, it has been widely accepted that synovium infiltration by T cells in chronic RA results from nonspecific trapping of T cells, e.g., in response to chemotactic factors released during the inflammatory reaction (19, 31) . Our results show that a large fraction ofsynovial T cells from two chronic RA patients recognizes a restricted set of EBV antigens, thus demonstrating that at least in some patients, T cell recruitment to the synovium is an active Ag-driven process. Although conflicting results have been obtained regarding the presence or absence of the EBV genome in synovia (32) (33) (34) , it is possible that EBVreactive T cells are expanded locally after recognition of EBV-infected cells within the joint. Alternatively, EBV could trigger cross-reactwe T cell responses against cellular proteins expressed in target organs. In this regard, several reports have described shared sequences between MHC alleles linked to increased RA susceptibility and EBV glycoproteins (35) (36) (37) (38) .
With respect to the second issue, implication of EBV in RA was first proposed several years ago, based on several clinical studies demonstrating increased EBV loads and anti-EBV Ab titers in the sera of RA patients (39, 40) . However, since no evidence for increased anti-EBV responses in RA lesions was provided, the physiopathological significance of these findings has remained controversial. In particular, the possibility that these clinical observations reflected a general alteration of immune responses due to chronic inflammation rather than an active participation of EBV infection in RA pathogenesis could not be ruled out. In this regard, our demonstration that EBV-reactive T cells are enriched within the joints of chronic 1LA patients provides, for the first time, a direct link between EBV and RA. Furthermore, the fact that these patients showed concomittantly high anti-EBV Ab titers suggests that increased anti-EBV serological responses previously found in a large fraction of chronic RA patients (39, 40) is associated with specific activation of EBV-reactive T cells within the lesions. Although our results suggest that EBV-reactive T cells in RA lesions are very likely to be pathogenic, it remains to be established definitively whether these cells exert harmful effects, for example, through direct cytotoxicity or release of inflammatory cytokines activating T cell-independent joint erosion (e.g., mediated by synoviocytes) (19) . Analysis of the in vivo behavior of these cells (e.g., in SCID/human models) will certainly help resolve these issues.
Whether or not anti-EBV responses in RA are directed against a restricted set of antigens is another interesting question. At present, a comparison of EBV responses between RA and non-RA individuals remains difficult, because none of the studies performed to date have really addressed T cell responses against EBV lytic proteins in non-RA EBV-mfected individuals (30) . Moreover, the fact that some BLC-reactive synovial T cell clones do not respond to BMLF1 or BZLF1 in COS transfection assays strongly suggests recognition of a larger set of EBV proteins by ILA patientderived T cells. Despite this, biased anti-EBV responses toward proteins of the virus rephcative cycle in RA patients is strongly suggested by the following observations. As mentioned before, EBV is known to enter the lytic cycle only in a minority of cells in BLC cultures. Therefore a dominant response against proteins expressed at that stage could explain both the decreased cytotoxic responses against autologous BLC frequently observed in RA patients (41, 42) and our inability to detect significant killing of BLC by synovial CTL in standard cytotoxicity assays (Table 4 ). It is noteworthy that this pecufiar behavior could also explain why synovial CD8 + T cell responses to EBV have not been detected before, because specificity of these cells is classically established through cytotoxicity assays.
Beyond the field of autoimmunity, these observations provide new insights into the fine specificity of the anti-EBV T cell response and the immune control of EBV reactivation, because they provide the first clear-cut evidence that the BZLF1 and BMLF1 EBV-transactivating proteins can be targets for CD8 + T cells. T cell recognition of such proteins has been suspected in several EBV-linked pathological situations (e.g., acute infectious mononucleosis, nasopharyngeal carcinoma, EBV reactivation in immunodepressed patients) during which serological Ab titers against BZLF1 product and other early antigens are significantly increased (for review see reference 30). However, technical limitations have hampered direct analysis of T cell responses directed against EBV lytic antigens. The physiological significance of BZLF1/BMLF1 recognition by T cells can be inferred from the function of these proteins during virus replication. BZLF1 is the first gene expressed draring the immediate early stage of the EBV lytic cycle, and it is thought to turn on expression of many other immediate early genes (43) . BMLF1 is a delayed immediate early gene with promiscuous transactivating properties that acts synergistically with BMLF1 and another EBV transactivator, B1LLF1, in in vitro assays (43) . It is therefore likely that T cell responses against these two key transactivators of EBV lytlc infection play a central role in controlling virus spreading under physiological and pathological situations. With the recent development of murine models allowing in vivo analysis of anti-EBV human T cell responses (44) , this hypothesis can now be tested.
